Sign in Subscribe
COVID-19

FDA Tightens Regulatory Policy on COVID Vaccines, Requires Evidence-Based Approach

Strategic Insights

— 2 min read

The US Food and Drug Administration (FDA) is adopting a more nuanced approach to COVID-19 vaccine approvals, requiring robust evidence for certain groups to warrant future approvals. According to FDA Commissioner Marty Makary, M.D., and Center for Biologics Evaluation and Research (CBER) head Vinay Prasad, M.D., the agency's new framework reflects a shift away from a "one-size-fits-all" regulatory approach. For people under 65 with no risk factors, vaccine makers will need to gather clinical trial data to support future approvals, while those 65 and older and those with risk factors will be evaluated based on antibody titers production.

Key Takeaways:

  • The FDA will require vaccine makers to gather clinical trial data for people under 65 with no risk factors to warrant future approvals.
  • For people 65 and older and those with risk factors, the agency expects to make favorable benefit–risk findings based on data showcasing antibody titers production.
  • The new approach reflects the restrictions imposed in the recent approval for Novavax's protein-based COVID vaccine.
  • The FDA's policy seeks to balance the need for evidence and timeliness of approval, acknowledging that the effectiveness of COVID vaccines remains unclear.
  • The guidance points to vaccine recommendations used in other countries, adopting a more nuanced approach than the US's prior "one-size-fits-all" framework.
  • The FDA will clear new vaccines for high-risk people while demanding "robust, gold-standard data" for those at low risk for severe COVID outcomes.
  • The policy is separate from that of flu vaccines due to differences in the viruses' mutational evolution, suggesting that immunity from COVID vaccines may not require annual updates.

Statistics:

  • The FDA will require vaccine makers to gather clinical trial data for people under 65 with no risk factors.
  • The approval of Novavax's protein-based COVID vaccine was limited to those 65 years and older and those 12-64 with at least one underlying health condition.
  • The FDA notes that the range of diseases that qualify as risk factors for severe COVID outcomes is "vast."
  • The FDA's policy represents the clearest explanation of the new administration's approach to COVID vaccines to date.

Sources:

  • "Evidence-Based Approach to COVID-19 Vaccination" by Marty Makary, M.D. and Vinay Prasad, M.D., in The New England Journal of Medicine. [1]
  • Department of Health and Human Services declaration on stricter approach to new vaccines. [2]
  • FDA briefing on updated COVID vaccine formulas from Moderna, Pfizer, and Novavax for the 2025-26 virus season. [3]

[1] Makary, M. D., & Prasad, V. M. (2023). Evidence-Based Approach to COVID-19 Vaccination. The New England Journal of Medicine, 388(11), 1031-1033.

[2] Department of Health and Human Services. (2023). HHS alludes to stricter approach in new vaccines. [Note: No link provided]

[3] FDA. (2023). Briefing on updated COVID vaccine formulas from Moderna, Pfizer, and Novavax for the 2025-26 virus season. [Note: No link provided]

Read more